Shopping Cart
Remove All
Your shopping cart is currently empty
PF-06747711 is an effective and selective retinoic acid receptor-related orphan C2 inverse agonist (IC50: 4.1 nM). PF-06747711 also has anti-skin inflammatory activity.


| Description | PF-06747711 is an effective and selective retinoic acid receptor-related orphan C2 inverse agonist (IC50: 4.1 nM). PF-06747711 also has anti-skin inflammatory activity. |
| Targets&IC50 | RORC2:4.1 nM |
| In vitro | PF-06747711 decreases IL-17 production by human Th17 cells (IC50: 9.5 nM) [1]. |
| In vivo | In mice, PF-06747711 (10, 30, and 100 mg/kg, p.o., daily over 5 days) suppresses ear swelling in a dose-dependent manner[1]. |
| Molecular Weight | 497.51 |
| Formula | C26H26F3N5O2 |
| Cas No. | 1892576-58-7 |
| Relative Density. | 1.34 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 41.67 mg/mL (83.76 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (4.02 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.